In Q1 2026, DuPont de Nemours finalized the sale of its Aramids business and completed the prior separation of its Electronics segment, segments now reported as discontinued operations. These strategic moves reposition the company to concentrate on Healthcare & Water Technologies alongside Diversified Industrials. This operational refocus follows a broader restructuring effort starting in 2025, marking a decisive pivot toward specialty chemicals tailored to critical markets requiring technical innovation and regulatory expertise. DuPont sustains a strong liquidity position supported by $2.0 billion in working capital and $0.7 billion in cash, providing financial flexibility amid geopolitical uncertainties. Growth prospects center on new product introductions and recent acquisitions aimed at expanding medical packaging and water treatment capabilities.